BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2024-02

167 industry Phase 2/3 trial readout(s) and 23 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2024-01 | 2024-03 →

FDA decision events

DateEventStatusCompanyDrugSource
2024-02-01FDA approvalapprovedBAXTER HLTHCARE CORP BAXCEFAZOLIN IN DEXTROSEApproved 2024-02-01: CEFAZOLIN IN DEXTROSE (NDA207131 SUPPL9)
2024-02-02FDA AdComheldAdCom 2024-02-02: Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee
2024-02-06FDA AdComheldAdCom 2024-02-06: General Hospital and Personal Use Devices Panel of the Medical Devices Advisory Committee
2024-02-09Complete response letterapproved sinceXeris Pharmaceuticals, Inc. XERSGvoke (glucagon) injectionCRL 2024-02-09: Xeris Pharmaceuticals, Inc. NDA 212097/S-012 (Gvoke (glucagon) injection)
2024-02-09FDA approvalapprovedTAKEDA PHARMS USA TAKEOHILIAApproved 2024-02-09: EOHILIA (NDA213976 ORIG1)
2024-02-13FDA AdComheldAdCom 2024-02-13: Circulatory System Devices Panel of the Medical Devices Advisory Committee
2024-02-13FDA approvalapprovedIPSENONIVYDEApproved 2024-02-13: ONIVYDE (NDA207793 SUPPL16)
2024-02-13FDA approvalapprovedBTG INTLAURLUMYNApproved 2024-02-13: AURLUMYN (NDA217933 ORIG1)
2024-02-13FDA approvalapprovedGALEPHARLEGUBETIApproved 2024-02-13: LEGUBETI (NDA215040 ORIG1)
2024-02-14FDA approvalapprovedBAXTER HLTHCARE CORP BAXPANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDEApproved 2024-02-14: PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE (NDA217512 ORIG1)
2024-02-15FDA approvalapprovedEMD SERONO INCTEPMETKOApproved 2024-02-15: TEPMETKO (NDA214096 SUPPL3)
2024-02-15FDA approvalapprovedDAIICHI SANKYOENHERTUApproved 2024-02-15: ENHERTU (BLA761139 SUPPL26)
2024-02-16FDA approvalapprovedASTRAZENECA AZNTAGRISSOApproved 2024-02-16: TAGRISSO (NDA208065 SUPPL30)
2024-02-16FDA approvalapprovedGENENTECHXOLAIRApproved 2024-02-16: XOLAIR (BLA103976 SUPPL5245)
2024-02-17FDA approvalapprovedHAUN SPECIALTY GASES INCCARBON DIOXIDE USPApproved 2024-02-17: CARBON DIOXIDE, USP (NDA219303 ORIG1)
2024-02-20FDA approvalapprovedJANSSEN BIOTECHTECVAYLIApproved 2024-02-20: TECVAYLI (BLA761291 SUPPL3)
2024-02-22Complete response lettercomplete responseVenatorx Pharmaceuticals, Inc.CRL 2024-02-22: Venatorx Pharmaceuticals, Inc. NDA 217556
2024-02-22FDA approvalapprovedORCHID PHARMAEXBLIFEPApproved 2024-02-22: EXBLIFEP (NDA216165 ORIG1)
2024-02-23FDA approvalapprovedGILEAD SCIENCES INC GILDBIKTARVYApproved 2024-02-23: BIKTARVY (NDA210251 SUPPL18)
2024-02-23FDA approvalapprovedALVOTECH USA INC ALVOSIMLANDIApproved 2024-02-23: SIMLANDI (BLA761299 ORIG1)
2024-02-26Complete response lettercomplete responseMinerva Neurosciences, Inc NERV(roluperidone) extended-release tabletsCRL 2024-02-26: Minerva Neurosciences, Inc NDA 217002 ((roluperidone) extended-release tablets)
2024-02-28FDA approvalapprovedGILEAD SCIENCES INC GILDVEKLURYApproved 2024-02-28: VEKLURY (NDA214787 SUPPL26)
2024-02-29FDA approvalapprovedHUGEL INCLETYBOApproved 2024-02-29: LETYBO (BLA761225 ORIG1)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2024-02 est.P3Medlab ClinicalNCT04808531 NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic CancersCancer Related Painunknown360
2024-02-01 est.P1/P2Taiwan Leader Biotech Corp.NCT02826837 LEAC-102 for Advanced Colorectal CancerAdvanced Colorectal Cancerunknown30
2024-02-01 est.P2/P3NeuroplastNCT03935724 Stem Cells in Spinal Cord InjurySpinal Cord Injuries; Acute Spinal Cord Injury; Paraplegia, Spinal; Paraplegia; Traumaticunknown16
2024-02-01P2Novartis Pharmaceuticals NVSNCT04066244 Study of Safety and Proof of the Mechanism of BLZ945 in ALS PatientsAmyotrophic Lateral Sclerosisterminated28
2024-02-01P2BeiGeneNCT04948697 A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCAdvanced Hepatocellular Carcinomacompleted94
2024-02-01P2/P3ContinueYou, LLCNCT05227339 RAE (Realize, Analyze, Engage)Substance Use Disorders; Treatment Adherence and Compliancecompleted209
2024-02-01 est.P2Zylorion HealthNCT05438758 Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension StudyTreatment Resistant Major Depressive Disorderwithdrawn
2024-02-01P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05481645 Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.Advanced Endometrial Cancer; Sarcoma of Uterusterminated71
2024-02-01P2Renovion, Inc.NCT05495243 Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and CoughNon-cystic Fibrosis Bronchiectasiscompleted40
2024-02-01P2Sanotize Research and Development corp.NCT05877313 Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts)Verruca Plantariscompleted20
2024-02-02P1/P2GlaxoSmithKlineNCT04886154 A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and AdultsInfections, Meningococcalcompleted1440
2024-02-02P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05011019 A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I NeurofibromatosisNeurofibromatosis and Malignant Peripheral Nerve Sheath Tumorsterminated22
2024-02-02P3Neurocrine UK Limited NBIXNCT05063994 Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal HyperplasiaCongenital Adrenal Hyperplasiacompleted55
2024-02-02P1/P2Theseus PharmaceuticalsNCT05160168 A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)Gastrointestinal Stromal Tumors (GIST); Neoplasms, Connective Tissue; Neoplasms, Connective and Softterminated32
2024-02-02P2ARS Pharmaceuticals, Inc. SPRYNCT05363670 Administration of ARS-1 or Albuterol in Subjects With Persistent AsthmaAsthmacompleted18
2024-02-02P3Cara Therapeutics, Inc.NCT05387707 Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Pruritus; Atopic Dermatitisterminated287
2024-02-02P2MC2 TherapeuticsNCT05482698 The MC2-25 Cream in Subjects wITh CHronic KIdNEy Disease-aSsociated prurituS (ITCHINESS) TrialChronic Kidney Disease-associated Prurituscompleted111
2024-02-02P3GlaxoSmithKlineNCT05630833 A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)Urinary Tract Infectionscompleted380
2024-02-02P2Lallemand Health SolutionsNCT05766306 The Efficacy of a Probiotic Blend on Stress in Moderately Stressed TeensStresscompleted30
2024-02-02P1/P2Nasus Pharma NSRXNCT06205134 Comparative Bioavailability of Intranasal EpinephrineAnaphylaxis; Anaphylactic Reactioncompleted12
2024-02-02 est.P2HvivoNCT06254820 Dose, Safety, and Pathogenicity of a New Influenza B StrainInfluenza Bunknown60
2024-02-03 est.P3Bausch Health Americas, Inc.NCT04151719 An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic CancerPancreatic Cancerwithdrawn
2024-02-04P1/P2Suzhou Junjing BioSciences Co., Ltd.NCT04993391 AP-L1898 Capsule in Patients With Non-small Cell Lung CancerLung Cancerterminated32
2024-02-05P2Regeneron Pharmaceuticals REGNNCT04698187 CMP-001 in Combination With Nivolumab in Subjects With Advanced MelanomaMelanoma; Advanced Melanoma; Metastatic Melanoma; Unresectable Melanomaterminated44
2024-02-05P2Hansa Biopharma ABNCT05049850 A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to TransplantationKidney Transplantation in Highly Sensitized Patientsterminated3
2024-02-06P3AbbVie ABBVNCT03725202 A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell ArteritisGiant Cell Arteritis (GCA)completed429
2024-02-06P1/P2Numab Therapeutics AGNCT04442126 A Study of NM21-1480 in Adult Patients With Advanced Solid TumorsAdvanced Solid Tumor; Non-small Cell Lung Cancer; Colorectal Cancer; Squamous Cell Carcinoma; Ovariaterminated52
2024-02-06P2Sanofi SNYNCT05104892 Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe AsthmaAsthmacompleted196
2024-02-06P2Denovo Biopharma LLCNCT05113771 A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRDTreatment Resistant Depressioncompleted197
2024-02-06P3Pfizer PFENCT05371652 A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese ParticipantsAcute Migrainecompleted241
2024-02-06 est.P3Neutec Ar-Ge San ve Tic A.ŞNCT05890638 Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination Nebuliser Solutions in Stable ChronicCOPDunknown74
2024-02-07P3Merck Sharp & Dohme LLC MRKNCT03976323 Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339Carcinoma, Nonsquamous Non-small-cell Lungcompleted1003
2024-02-07P3AstraZeneca AZNNCT05056727 A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at RiRenal Insufficiency, Chronic; Hyperkalemiaterminated1112
2024-02-07P3Samyang Biopharmaceuticals CorporationNCT05207514 Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast CancerBreast Cancerterminated26
2024-02-07P1/P2BioInvent International ABNCT05555251 BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid TumorsHER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Metastatic Breast Cancer; Mterminated18
2024-02-07P2TriGemX Bio, Inc.NCT06019559 A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833Obesitycompleted155
2024-02-08P2Ionis Pharmaceuticals, Inc. IONSNCT04014335 A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA NephropaPrimary IgA Nephropathycompleted23
2024-02-08P3EstetraNCT04209543 Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)Vasomotor Symptoms; Menopausal Symptomscompleted1570
2024-02-08P3AstraZeneca AZNNCT04739761 A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast CancerBreast Canceractive not recruiting506
2024-02-08P2Janssen Research & Development, LLCNCT04836559 A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in EpilepsyFocal Onset Seizurescompleted110
2024-02-08P2Eirion Therapeutics Inc.NCT04985916 ET-01 in Subjects With Lateral Canthal Lines, LCL-210Lateral Canthal Lines, LCL; Crow's Feetcompleted280
2024-02-08P3Eli Lilly and Company LLYNCT05169567 Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast CancerBreast Neoplasm; Neoplasm Metastasisactive not recruiting368
2024-02-08P2Kiniksa Pharmaceuticals, Ltd. KNSANCT05198310 Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at LeArthritis, Rheumatoidcompleted145
2024-02-08P2TBF Genie TissulaireNCT05250726 Use of a Treated, Devitalized and Sterile Meniscus Segment (MENISC-T) in the Treatment of Scaphotrapeziotrapezoid OsteoarthritisOsteoarthritis Handcompleted14
2024-02-08P3Bristol-Myers Squibb BMYNCT05297565 A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete ResectionMelanomacompleted14
2024-02-09P2Spruce Biosciences SPRBNCT04457336 A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAHCongenital Adrenal Hyperplasiaterminated96
2024-02-09P2GlaxoSmithKlineNCT05084508 A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to HeChickenpoxcompleted800
2024-02-12P3AbbVie ABBVNCT04435600 A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease SymptomsPsoriasiscompleted139
2024-02-12P2COMPASS Pathways CMPSNCT05312151 The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderPost Traumatic Stress Disordercompleted22
2024-02-12P2EyePoint Pharmaceuticals, Inc. EYPTNCT05383209 Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)Nonproliferative Diabetic Retinopathycompleted77
2024-02-12P2Aphaia Pharma US LLCNCT05803772 A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation in Subjects With a Pathological Oral Glucose Tolerance TestPreDiabetes; Glucose Tolerance Impairedcompleted31
2024-02-13P1/P2OBI Pharma, IncNCT03592264 A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid TumorsSolid Tumor; Pancreatic Adenocarcinomaterminated68
2024-02-13P3AstraZeneca AZNNCT05251909 Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)Eosinophilic Gastritis; Eosinophilic Gastroenteritisterminated12
2024-02-13P2/P3Annovis Bio Inc. ANVSNCT05686044 A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate ADAlzheimer Diseasecompleted351
2024-02-13P3Celltrion Pharm, Inc.NCT07564726 Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High CholesterolHypertension; Hypercholesterolemiacompleted163
2024-02-14P1/P2BioMarin Pharmaceutical BMRNNCT02576795 Gene Therapy Study in Severe Haemophilia A Patients (270-201)Severe Haemophilia Acompleted15
2024-02-14P2Bukwang PharmaceuticalNCT04377945 Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual ComponentsDyskinesias; Parkinson Diseaseterminated41
2024-02-14P2Ascend Biopharmaceuticals Ltd AAWHNCT04416516 Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway InhibitorBasal Cell Carcinoma; Basal Cell Nevus Syndromecompleted21
2024-02-14P1/P2K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.NCT05199337 Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) AmyloidosisAmyloidosis; AL Amyloidosiscompleted18
2024-02-14P3Huons Co., Ltd.NCT05743764 HU007 in Patients with Dry Eye SyndromeDry Eye Diseasecompleted328
2024-02-14P2Wuhan YZY Biopharma Co., Ltd.NCT06266091 Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific AntibodyMalignant Ascitescompleted115
2024-02-14P1/P2GlaxoSmithKlineNCT06655818 Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMMRelapsed/Refractory Multiple Myelomaterminated4
2024-02-15P3Albireo, an Ipsen CompanyNCT03659916 Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFICProgressive Familial Intrahepatic Cholestasiscompleted116
2024-02-15P3GlaxoSmithKlineNCT04091451 Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age Herpes Zostercompleted1430
2024-02-15P2/P3Laurent Pharmaceuticals Inc.NCT04417257 Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in AdultsCOVID-19 Diseaseterminated351
2024-02-15P2Anthos Therapeutics, Inc.NCT04755283 Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial FibrillationAtrial Fibrillation (AF); Strokeactive not recruiting1287
2024-02-15 est.P3Shanghai Henlius BiotechNCT04806945 A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical CancerCervical Cancerwithdrawn
2024-02-15P1/P2Celularity Incorporated CELUNCT05207722 CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or GastroesophageaMetastatic HER2 Positive Gastroesophageal Junction Cancerterminated1
2024-02-15 est.P1/P2LaSanta S A SNCT05272865 Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THCNausea Post Chemotherapy; Vomiting; Cancer Pain; Cancer Related Pain; Neoplasmsunknown334
2024-02-15P3Eli Lilly and Company LLYNCT05288166 A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to HormonaProstatic Neoplasms; Neoplasm Metastasis; Urogenital Neoplasms; Physiological Effects of Drugs; Antiactive not recruiting925
2024-02-16P2DiaVacs, Inc.NCT02354911 Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes TherapyType 1 Diabeteswithdrawn
2024-02-16P3Merck Sharp & Dohme LLC MRKNCT03221426 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) AdenocarcinoGastric Cancer; Gastroesophageal Junction Cancercompleted1007
2024-02-16P1/P2IGM Biosciences, Inc.NCT04082936 A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin LymphomaNon-Hodgkin Lymphoma; Follicular Lymphoma; DLBCL; Mantle Cell Lymphoma; Marginal Zone Lymphomaterminated97
2024-02-16P3SK Life Science, Inc.NCT04557085 Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POSPartial Seizure; Focal Seizurecompleted519
2024-02-16P2Sanofi SNYNCT04659603 Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid TumorsBreast Cancer Metastatic; Pancreatic Carcinoma Metastaticterminated50
2024-02-16P3Merck Sharp & Dohme LLC MRKNCT04882241 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) AdenocarcinoGastric Cancer; Gastroesophageal Junction Cancercompleted120
2024-02-16P3Kissei Pharmaceutical Co., Ltd.NCT05445167 A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and PainUterine Fibroids (MeSH Heading: Leiomyoma)completed89
2024-02-16P3Merck Sharp & Dohme LLC MRKNCT05696080 Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)Pneumococcal Infectioncompleted518
2024-02-18P2Calliditas Therapeutics Suisse SANCT05323656 A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)Squamous Cell Carcinoma of Head and Neckcompleted55
2024-02-19P2/P3Daehwa Pharmaceutical Co., Ltd.NCT03315364 Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line TherapyRecurrent or Metastatic Breast Canceractive not recruiting549
2024-02-19P3Eli Lilly and Company LLYNCT04527380 A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset AnkylosingJuvenile Psoriatic Arthritis; Enthesitis Related Arthritisactive not recruiting101
2024-02-19P3GlaxoSmithKlineNCT05966090 A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy AdultsRespiratory Syncytial Viruses; Respiratory Syncytial Virus Infectionscompleted530
2024-02-19P3Janssen Research & Development, LLCNCT06134804 A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administratiInvasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Preventioncompleted959
2024-02-20P1/P2TransThera Sciences (Nanjing), Inc.NCT04742959 Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsAdvanced Solid Tumor; Cholangiocarcinoma; HER2-negative Breast Cancer; Triple Negative Breast Cancercompleted203
2024-02-20P3Ultragenyx Pharmaceutical Inc RARENCT05139316 A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)Glycogen Storage Disease Type IAcompleted52
2024-02-20P2Endeavor Biomedicines, Inc.NCT05199584 A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsSolid Tumors With PTCH1 Loss-of-function Mutationscompleted20
2024-02-20P2Disc Medicine, Inc IRONNCT05308472 Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPPErythropoietic Protoporphyriacompleted75
2024-02-20P2/P3Qilu Pharmaceutical Co., Ltd.NCT05554913 Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced ThrombocytopeniaChemotherapy-induced Thrombocytopeniacompleted63
2024-02-20P3Biosplice Therapeutics, Inc.NCT05603754 Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis (STRIDES)Knee Osteoarthritiscompleted499
2024-02-20P3Otsuka Pharmaceutical Co., Ltd.NCT05683340 A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL CholesterolemiaHyper-low-density Lipoprotein (LDL) Cholesterolemiacompleted96
2024-02-20P2Allogene Therapeutics ALLONCT05714345 Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell TherapyRelapsed/Refractory Large B Cell Lymphomaterminated2
2024-02-20P2Haisco Pharmaceutical Group Co., Ltd.NCT05795517 Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)Hypercholesterolemiacompleted210
2024-02-20P1/P2Beijing Kanova Biopharmaceutical Co., LTDNCT05991661 XKH001 Injection in Healthy SubjectsAsthmacompleted24
2024-02-21P3Pharmacyclics LLC.NCT02947347 Study of Ibrutinib and Rituximab in Treatment Naïve Follicular LymphomaFollicular Lymphomacompleted445
2024-02-21P3Biogen BIIBNCT04089566 Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyMuscular Atrophy, Spinalcompleted145
2024-02-21P2LigaChem Biosciences, Inc.NCT05225558 A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA BacteremiaMRSA Bacteremiaterminated40
2024-02-21P2TBF Genie TissulaireNCT05302609 Evaluation of SclerFIX Graft in Scleral Thinning After Exeresis of Tumors of the Ocular SurfaceScleral Thinningterminated17
2024-02-21P3PolarityTENCT05372809 Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUsDiabetic Footterminated42
2024-02-21P2ONL TherapeuticsNCT05730218 A Phase 2 Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Mac-off Retinal DetachmentRhegmatogenous Retinal Detachment - Macula Offcompleted136
2024-02-21P2CSPC Ouyi Pharmaceutical Co., Ltd.NCT05858047 An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque PsoriasisEffects, Drug Sidecompleted93
2024-02-22P2Bristol-Myers Squibb BMYNCT04572893 Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other CausalitiesPrimary Familial Dilated Cardiomyopathyterminated41
2024-02-22P2BeiGeneNCT04716634 Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid TumorsAdvanced Solid Tumorscompleted84
2024-02-22P3Intra-Cellular Therapies, Inc.NCT04985942 Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderMajor Depressive Disordercompleted485
2024-02-22P3Xuanzhu Biopharmaceutical Co., Ltd.NCT05077449 A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast CancerAdvanced Breast Canceractive not recruiting300
2024-02-22P2PT Bio FarmaNCT05727215 Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of AgeCOVID-19completed150
2024-02-22P2Xeris Pharmaceuticals XERSNCT05823012 Study of XP-8121 For the Treatment of Adult Subjects With HypothyroidismHypothyroidismcompleted46
2024-02-22P2Skye Bioscience, Inc. SKYENCT06144918 Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye PressurePrimary Open Angle Glaucoma; Ocular Hypertensioncompleted56
2024-02-23P3Incyte Corporation INCYNCT04680052 A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients WitFollicular Lymphoma; Marginal Zone Lymphomaactive not recruiting654
2024-02-23P1/P2GlaxoSmithKlineNCT05496231 A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of AgeCervical Intraepithelial Neoplasiacompleted1080
2024-02-23P3LEO PharmaNCT05919082 A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque PsoriasisStable Plaque Psoriasiscompleted604
2024-02-23P2/P3Gilead Sciences GILDNCT05996744 Study of Obeldesivir in Children and Adolescents With COVID-19COVID-19terminated3
2024-02-23P2MEDA Pharma GmbH & Co. KGNCT06126952 Azelastine Allergen Chamber - Onset of Action StudySeasonal Allergic Rhinitiscompleted84
2024-02-24P3Vertex Pharmaceuticals Incorporated VERXNCT04183790 Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and OlderCystic Fibrosiscompleted64
2024-02-24P2Transposon Therapeutics, Inc.NCT04993768 A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)Progressive Supranuclear Palsycompleted42
2024-02-26P2Epizyme, Inc.NCT02601950 A Study of Tazemetostat in Adult Participants With Soft Tissue SarcomaMalignant Rhabdoid Tumors (MRT); Rhabdoid Tumors of the Kidney (RTK); Atypical Teratoid Rhabdoid Tumcompleted267
2024-02-26P2OnQuality Pharmaceuticals (USA) LLCNCT04088318 A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer PatientsHand-Foot Skin Reaction (HFSR)unknown170
2024-02-26P24SC AGNCT04393753 Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1Merkel Cell Carcinomacompleted19
2024-02-26P2Pliant Therapeutics, Inc. PLRXNCT04480840 Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)Primary Sclerosing Cholangitiscompleted121
2024-02-26P3Asahi Kasei Therapeutics, ABNCT04541043 Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)Primary IgA Nephropathycompleted119
2024-02-26P2BeiGeneNCT04643470 Zanubrutinib in Participants With Active Proliferative Lupus NephritisLupus Nephritiscompleted177
2024-02-26P2Bristol-Myers Squibb BMYNCT04766892 A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnTHeart Failure With Preserved Ejection Fractioncompleted30
2024-02-26P3Cara Therapeutics, Inc.NCT05356403 CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe PruritusChronic Kidney Diseases; Pruritusterminated105
2024-02-26P2BeiGeneNCT05461794 Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell Carcinomaterminated96
2024-02-26P3Daewoong Pharmaceutical Co. LTD.NCT05505994 The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on MetforminDiabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders; Metabolic Disease; Endocunknown340
2024-02-26P3Protox Inc.NCT06124794 The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar LinesGlabellar Frown Linescompleted155
2024-02-27P2Sanaria Inc.NCT03503058 Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted MalariaMalariacompleted345
2024-02-27P3Takeda TAKNCT03596866 A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung CancerALK+ Advanced NSCLCcompleted248
2024-02-27P2Hansa Biopharma ABNCT03943589 A Study of Imlifidase in Patients With Guillain-Barré SyndromeGuillain-Barré Syndrome (GBS)completed30
2024-02-27P2Eli Lilly and Company LLYNCT04640077 A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Cognitive Impairmentcompleted95
2024-02-27P2Dragonboat Biopharmaceutical Company LimitedNCT04718584 the Efficacy and Safety of LDP in Patients With Urinary and Male Genital TumorsBladder Cancer; Renal Carcinoma; Advanced Penile Carcinomacompleted27
2024-02-27P2Neuren Pharmaceuticals LimitedNCT05025332 An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)Pitt Hopkins Syndromecompleted28
2024-02-27P1/P2Alladapt Immunotherapeutics, Inc.NCT05243719 Open-label Extension Study of ADP101Food Allergyterminated45
2024-02-27P2Palobiofarma SLNCT05262218 Therapeutic Effect of PBF-680 in Patients With COPDCOPDcompleted174
2024-02-27P3Eli Lilly and Company LLYNCT05462756 A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple DailyType 2 Diabetes; Type 2 Diabetes Treated With Insulincompleted730
2024-02-27P2Pulmatrix Inc. PULMNCT05667662 Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPAABPAterminated8
2024-02-27 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT05792410 A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.HER2 Low Advanced or Metastatic Breast Cancerunknown300
2024-02-27P2Modern Biosciences Ltd MDRNNCT05951296 A Study to Investigate Leramistat in Patients With IPFIdiopathic Pulmonary Fibrosiswithdrawn
2024-02-27P2Viking Therapeutics, Inc. VKTXNCT06068946 VK2735 for Weight Management Phase 2Weight Losscompleted176
2024-02-28P2/P3NeuroRx, Inc.NCT03395392 NRX-101 for Bipolar Depression With Subacute Suicidal IdeationBipolar Depression; Suicidal Ideation and Behaviorcompleted74
2024-02-28P3Novartis Pharmaceuticals NVSNCT04047472 Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular DegenerationNeovascular Age-Related Macular Degenerationcompleted397
2024-02-28P2Elevation OncologyNCT04383210 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid TumorsLocally Advanced Solid Tumor; Metastatic Solid Tumor; Pancreatic Cancer; Lung Cancer; Head and Neck terminated54
2024-02-28P3Sanofi SNYNCT04456673 Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 InflammationChronic Obstructive Pulmonary Diseasecompleted935
2024-02-28 est.P2Bristol-Myers Squibb BMYNCT04495010 Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant NivoMelanomawithdrawn
2024-02-28P2Hovid BerhadNCT04658823 Efficacy and Safety of Tocotrienols in CADASILCadasilcompleted50
2024-02-28P2Colgate Palmolive CLNCT04750902 A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100Dental Cariescompleted2025
2024-02-28P2AkesoNCT04868708 A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical CancerRecurrent or Metastatic Cervical Cancercompleted50
2024-02-28P2TransThera Sciences (Nanjing), Inc.NCT04919642 Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in CholangiocarcinomaCholangiocarcinoma; FGFR2 Fusion; FGFR2 Gene Mutation; FGFR1 Alteration; FGFR3 Alterationcompleted55
2024-02-28 est.P2National Vaccine and Serum Institute, ChinaNCT04941261 Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)Norovirus Infections; Norwalk Gastroenteritisunknown1716
2024-02-28P3Aerie PharmaceuticalsNCT05493111 A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512Dry Eye Diseasecompleted275
2024-02-28P2Pascoe Pharmazeutische Praeparate GmbHNCT05561257 Vitamin C as add-on Therapy in Patients With Acute Herpes ZosterNeuropathic Painterminated12
2024-02-28P2Zevra Therapeutics ZVRANCT05668754 Study of SDX in Patients With Idiopathic Hypersomnia (IH)Idiopathic Hypersomniacompleted66
2024-02-28 est.P1/P2DualityBio Inc.NCT05785728 A Study of DB-1202 Monotherapy in Advanced Solid TumorsAdvanced Solid Tumorunknown150
2024-02-28P2Changchun GeneScience Pharmaceutical Co., Ltd.NCT05936268 Safety and Efficacy of Genakumab for Injection in Patients With Gout FlareAcute Gout; Gout Flarecompleted106
2024-02-29P1/P2CelgeneNCT01997840 ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple MyelomaMultiple Myelomaterminated103
2024-02-29P3Denovo Biopharma LLCNCT03776071 A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Glioblastomacompleted260
2024-02-29P3Janssen Pharmaceutical K.K.NCT04397263 A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseaseCrohns Diseasecompleted38
2024-02-29P2Hutchison Medipharma LimitedNCT04849351 Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaMarginal Zone Lymphoma; Follicular Lymphomacompleted178
2024-02-29P1/P2Asklepion Pharmaceuticals, LLCNCT04852172 L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)Acute Vaso Occlusive Crisis (VOC)terminated30
2024-02-29P3Organon and Co OGNNCT05142774 Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic DermatitisAtopic Dermatitiscompleted728
2024-02-29P2Kind Pharmaceuticals LLCNCT05265325 A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on DialysisRenal Anemiacompleted175
2024-02-29P3Cingulate Therapeutics CINGNCT05286762 Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301ADHD; Attention Deficit Hyperactivity Disorder; ADHD - Combined Type; Attention Deficit Hyperactivitcompleted103
2024-02-29P3Cara Therapeutics, Inc.NCT05342623 A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe PruritusChronic Kidney Diseases; Pruritusterminated286
2024-02-29P2Supernus Pharmaceuticals, Inc. SUPNNCT05358821 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's DiseaseHuntington Diseasecompleted69
2024-02-29P2ARS Pharmaceuticals, Inc. SPRYNCT05496465 Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria FlaresUrticariacompleted21
2024-02-29P1/P2Dizal PharmaceuticalsNCT05844956 A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)Lymphoma, Non-Hodgkincompleted17
2024-02-29P2AlgoTherapeutixNCT05917912 EASE (Efficacy of ATX01 Study in Erythromelalgia)Erythromelalgiacompleted14
2024-02-29 est.P2E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.NCT06170840 A Study of QY101 Ointment in Subjects With Plaque PsoriasisPsoriasisunknown160

← 2024-01 | 2024-03 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.